CompletedPhase 3

Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia

United States593 participantsStarted 2005-11-18

Plain-language summary

The purpose of this study is to determine the safety and efficacy of iloperidone compared to placebo and an active comparator in the treatment of patients with schizophrenia in acute exacerbation.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * DSM-IV diagnosis of schizophrenia * PANSS-T of at least 70 at screening and baseline Exclusion Criteria: * Clinically significant disease of the heart, kidneys, liver or gastrointestinal system * DSM-IV diagnosis of psychiatric disorder other than schizophrenia

What they're measuring

Change From Baseline in Positive and Negative Symptom Scale Total (PANSS-T) Score

Timeframe: 4 weeks

Trial details

NCT IDNCT00254202

SponsorVanda Pharmaceuticals

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2006-09-26

Results submitted2024-04-01

View on ClinicalTrials.gov More Schizophrenia trials